bpc-157 tga RACGP How wellness clinics bend the

First, they come from different populations and trial designs than the cagrilintide studies SURPASS-2 compared tirzepatide with semaglutide in diabetes

Wixler, V., Zaytsev, I

In populations with type 2 diabetes, tirzepatide has demonstrated exceptional glycemic control

As a stable gastrin, BPC 157 has deep cell-protective activity, can exert biological effects without a carrier, and can stably exist in gastric juice for more than 24 hours, showing good oral bioavailability

BPC-157 is not FDA-approved for any medical use

There are weeks where nothing budges despite everything being on point, then a sudden drop that catches up